Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.

Type

Journal article

Journal

Br J Cancer

Publication Date

12/1991

Volume

64

Pages

1187 - 1188

Keywords

Antimetabolites, Antineoplastic, Breast Neoplasms, Drug Evaluation, Humans, Hydroxamic Acids, Ribonucleotide Reductases